Essex Bio-Technology
VC Fund
Hong Kong, Hong Kong
Essex Bio-Technology is a VC fund in Hong Kong focused on Health Care and Biotechnology. Essex Bio-Technology Limited (“EssexBio Group” and the “Company”) was incorporated in the Cayman Islands on 31st July, 2000 and has been listed on the Stock Exchange of Hong Kong since 27th June, 2001.Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and saleof biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Group also engaged in the research and development of bFGF products for new indications, as well as other ophthalmic pharmaceutical projects.A series of genetically engineered bio-pharmaceutical drugs have been successfully developed and three of them were classified as State-level Category I new drugs. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Essex Bio-Technology invests in
Stages Essex Bio-Technology invests in
Countries Essex Bio-Technology invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Therapeutics 1 (50%)
- Medical Device 1 (50%)
Stage
- Seed 1 (50%)
- Series B 1 (50%)
Country
- Singapore 1 (50%)
- United States 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Choon-Peng Ng
Senior Director (Commercial Strategy and Partnering)
|
Senior Director (Commercial Strategy and Partnering) | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| X-ZELL is an award-winning medical technology company founded by Y Combinator alumnus, Dr Sebastian Bhakdi. We develop innovative laboratory solutions that enable same-day cancer diagnoses from minimally invasive sample material – we call it next-generation cytology (NGC). | $4M / Seed / May 01, 2018 | ||
| MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients suffering from acquired and inherited disorders.The company is dedicated to advancing innovative treatments for patients with serious medical conditions. MeiraGTx's research and development efforts primarilyrevolve around gene therapy, a cutting-edge approach that involves modifying or replacing faulty genes to treat or prevent diseases. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring, and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland, and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. | $5M / Series B / Mar 16, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Essex Bio-Technology invest in?
Essex Bio-Technology invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Essex Bio-Technology?
Public channels for Essex Bio-Technology include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Essex Bio-Technology?
The team at Essex Bio-Technology includes Choon-Peng Ng (Senior Director (Commercial Strategy and Partnering)). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
